72788-94-4

Usage

Uses

Used in Pharmaceutical Synthesis:
(5-Chloropyrazin-2-yl)methanol is used as a key intermediate in the synthesis of pharmaceuticals for its ability to modulate biological processes. It plays a crucial role in the development of drug candidates, contributing to the creation of new medications with potential therapeutic benefits.
Used in Agrochemical Production:
In the agrochemical industry, (5-Chloropyrazin-2-yl)methanol serves as a building block for the production of various compounds. Its incorporation into agrochemicals can enhance their effectiveness in agricultural applications, such as pest control and crop protection.
Used in Organic Synthesis:
(5-Chloropyrazin-2-yl)methanol is utilized as a versatile building block in organic synthesis. Its unique structure allows for the production of a wide range of compounds, expanding the possibilities for chemical research and development in various fields, including medicine, agriculture, and materials science.

InChI:InChI=1S/C5H5ClN2O/c6-5-2-7-4(3-9)1-8-5/h1-2,9H,3H2

Upstream product

• 33332-25-1 methyl 5-chloropyrazine-2-carboxylate 
• 88625-24-5 5-chloropyrazine-2-carbaldehyde 
• 1261490-22-5 C₅H₃ClN₂O₂ 
• 34604-60-9 5-hydroxypyrazinoic acid 
• 36070-80-1 5-chloropyrazinoic acid 

Downstream Products

• 1257426-40-6 (6S)-2-nitro-6-({5-[4-(trifluoromethoxy)phenyl]-2-pyrazinyl}methoxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 
• 88625-24-5 5-chloropyrazine-2-carbaldehyde 
• 105985-21-5 2-chloro-5-pyrazinylmethyl chloride 
• 1591823-70-9 3-chloro-5-((1-((4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)methyl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile 
• 1591823-66-3 3-chloro-5-((1-((5-hydroxypyrazin-2-yl)methyl)-6-oxo-4-(trifluoromethyl)-1,6-dihydro pyrimidin-5-yl)oxy)benzonitrile 
• 1591827-01-8 3-chloro-5-((1-((5-chloropyrazin-2-yl)methyl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile 
• 1382999-00-9 methyl 3-{4-[5-formylpyrazin-2-yl]phenoxy}-2,2-dimethylpropanoate 
• 1382998-99-3 methyl 3-{4-[5-(hydroxyl-methyl)pyrazin-2-yl]phenoxy}-2,2-dimethylpropanoate 

Relevant academic research and scientific papers

THERAPEUTICALLY ACTIVE BICYCLIC-SULPHONAMIDES AND PHARMACEUTICAL COMPOSITIONS

Pharmaceutical compounds have a bicyclic-sulphonamide structure and pharmaceutical compositions including the compounds may be used in therapy as brain-cell-death protectants and may be used, for example, in the treatment of chronic neurodegenerative diseases. The compounds are active as inhibitors of N-acylethanolamine-hydrolysing acid amidase (NAAA) and may be used for the therapeutic treatment and prevention of pain and inflammatory disorders and other disorders which benefit from the modulation of fatty acid ethanolamides, particularly palmitoylethanolamide (PEA).

SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS

Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is (II) or (III); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3, L1, L2, R1a, R1b, R1c, and n are define herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

A Practical and Scalable Synthesis of a Glucokinase Activator via Diastereomeric Resolution and Palladium-Catalyzed C-N Coupling Reaction

Here we describe the research and development of a process for the practical synthesis of glucokinase activator (R)-1 as a potential drug for treating type-2 diabetes. The key intermediate, chiral α-arylpropionic acid (R)-2, was synthesized in high diastereomeric excess through the diasteromeric resolution of 7 without the need for a chiral resolving agent. The counterpart 2-aminopyrazine derivative 3 was synthesized using a palladium-catalyzed C-N coupling reaction. This efficient process was demonstrated at the pilot scale and yielded 19.0 kg of (R)-1. Moreover, an epimerization process to obtain (R)-7 from the undesired (S)-7 was developed.

Synthesis and biological evaluation of heteroaryl styryl sulfone derivatives as anticancer agents

Herein we disclose a series of novel heteroaryl styryl sulfone derivatives as potential anticancer agents. Structure-activity relationships of these newly synthesised compounds were explored with respect to the significance of the position and number of nitrogen atom of the heteroaryl ring for anti-proliferative activity in human cancer cell lines. A lead compound 14f was tested against a panel of cancerous and untransformed cell lines, and found to be highly potent against cancer cells with minimal toxicity in the untransformed cells. Further mechanistic studies uncovered that 14f caused cell-cycle arrest at the G2/M phase and induced apoptosis by targeting CDC25C and Mcl-1 proteins in A2780 ovarian cells.

FAAH INHIBITORS

The present disclosure relates to compounds useful as inhibitors of the enzyme Fatty Acid Amide Hydrolase (FAAH). The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the com

CONTINUOUS ARYCYCLIC COMPOUND

This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension,

NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY

The present invention relates to novel nitroimidazooxazines, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.

Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6 S)-2-nitro-6-{[4-(trifluoromethoxy) benzyl]oxy}-6,7-dihydro-5 H-imidazo[2,1-b][1,3]oxazine (PA-824)

New heterocyclic analogues of the potent biphenyl class derived from antitubercular drug PA-824 were prepared, aiming to improve aqueous solubility but maintain high metabolic stability and efficacy. The strategy involved replacement of one or both phenyl

4-OXO-1,4-DIHYDROQUINOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

NEW COMPOUNDS 806

The present invention relates to new compounds of formula (I) and to pharmaceutical composition containing said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds and to new intermediates useful in the preparation thereof.